Login to Your Account



SuperGen, Abbott Ending Deal For Cancer Compound Rubitecan

By Randall Osborne


Wednesday, March 6, 2002
More than two years after SuperGen Inc. said it “continued to enjoy a strong relationship” with partner Abbott Laboratories Inc., the pair’s worldwide sales and marketing collaboration valued at as much as $150 million has dissolved. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription